Population-level evidence for an autoimmune etiology of epilepsy.

PubWeight™: 1.09‹?› | Rank: Top 10%

🔗 View Article (PMC 4324719)

Published in JAMA Neurol on May 01, 2014

Authors

Mei-Sing Ong1, Isaac S Kohane2, Tianxi Cai3, Mark P Gorman4, Kenneth D Mandl2

Author Affiliations

1: Australian Institute of Health Innovation, University of New South Wales, Sydney, Australia2Children's Hospital Informatics Program at Harvard-Massachusetts Institute of Technology Health Sciences and Technology, Boston Children's Hospital, Boston, Massac.
2: Children's Hospital Informatics Program at Harvard-Massachusetts Institute of Technology Health Sciences and Technology, Boston Children's Hospital, Boston, Massachusetts3Center for Biomedical Informatics, Harvard Medical School, Boston, Massachusetts.
3: Department of Biostatics, Harvard School of Public Health, Boston, Massachusetts.
4: Center for Biomedical Informatics, Harvard Medical School, Boston, Massachusetts5Department of Neurology, Boston Children's Hospital, Boston, Massachusetts.

Articles cited by this

Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol (2008) 21.53

Early identification of refractory epilepsy. N Engl J Med (2000) 12.43

Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol (2011) 10.82

N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain (2010) 6.84

Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum (2002) 5.12

The long-term outcome of adult epilepsy surgery, patterns of seizure remission, and relapse: a cohort study. Lancet (2011) 2.99

Innate and adaptive immunity during epileptogenesis and spontaneous seizures: evidence from experimental models and human temporal lobe epilepsy. Neurobiol Dis (2007) 2.81

Serum antibodies in epilepsy and seizure-associated disorders. Neurology (2005) 2.53

Autoimmune epilepsy: clinical characteristics and response to immunotherapy. Arch Neurol (2012) 2.49

Adult-onset drug-refractory seizure disorder associated with anti-voltage-gated potassium-channel antibody. Epilepsia (2009) 1.88

Adverse events associated with the use of cyclosporine in patients with inflammatory bowel disease. Am J Gastroenterol (2008) 1.63

How accurate is ICD coding for epilepsy? Epilepsia (2009) 1.54

Inflammatory reactions in human medial temporal lobe epilepsy with hippocampal sclerosis. Brain Res (2002) 1.53

Recommendations for optimal ICD codes to study neurologic conditions: a systematic review. Neurology (2012) 1.51

Paediatric Hashimoto encephalopathy, refractory epilepsy and immunoglobulin treatment - unusual case report and review of the literature. Acta Paediatr (2010) 1.46

In vivo effects of antibodies from patients with anti-NMDA receptor encephalitis: further evidence of synaptic glutamatergic dysfunction. Orphanet J Rare Dis (2010) 1.33

Natural history of Crohn's disease: comparison between childhood- and adult-onset disease. Inflamm Bowel Dis (2010) 1.31

Immunological and clinical differences between juvenile and adult onset of systemic lupus erythematosus. Lupus (1999) 1.29

Epileptic seizures in systemic lupus erythematosus. Neurology (2004) 1.28

Inflammation in epilepsy: clinical observations. Epilepsia (2011) 1.23

Efficacy of anti-inflammatory therapy in a model of acute seizures and in a population of pediatric drug resistant epileptics. PLoS One (2011) 1.19

Clinical significance of glutamic acid decarboxylase antibodies in patients with epilepsy. Epilepsia (2009) 1.19

Long-term seizure outcomes following amygdalohippocampectomy. J Neurosurg (2003) 1.13

Clinical, serologic, and immunogenetic studies in childhood-onset systemic lupus erythematosus. Arthritis Rheum (1993) 1.09

Development and validation of a case definition for epilepsy for use with administrative health data. Epilepsy Res (2012) 1.05

Sodium valproate inhibits production of TNF-alpha and IL-6 and activation of NF-kappaB. Brain Res (2000) 1.05

Steroids in intractable childhood epilepsy: clinical experience and review of the literature. Seizure (2005) 1.05

Features associated with epilepsy in the antiphospholipid syndrome. J Rheumatol (2004) 0.96

Corticosteroids as treatment of epileptic syndromes with continuous spike-waves during slow-wave sleep. Epilepsia (2009) 0.94

Epilepsy: an autoimmune disease? J Neurol Neurosurg Psychiatry (2000) 0.90

Influence of age at disease onset in the outcome of paediatric systemic lupus erythematosus. Rheumatology (Oxford) (2009) 0.90

Drug-induced systemic lupus erythematosus after 7 years of treatment with carbamazepine. Acta Biomed (2006) 0.88

Corticosteroids enhance convulsion susceptibility via central mineralocorticoid receptors. Psychoneuroendocrinology (1995) 0.88

Seizures in patients with systemic lupus erythematosus: data from LUMINA, a multiethnic cohort (LUMINA LIV). Ann Rheum Dis (2007) 0.88

Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study. Ann Rheum Dis (2012) 0.86

Inhibitory effect of carbamazepine on inflammatory mediators produced by stimulated glial cells. Neurosci Res (2000) 0.85

Attenuation of epileptogenesis by nonsteroidal anti-inflammatory drugs in the rat. Neuropharmacology (1991) 0.85

Autoantibodies in the patient with drug-resistant epilepsy: are we missing a treatable etiology? Arch Neurol (2012) 0.83

The immunosuppressant cyclosporin A inhibits recurrent seizures in an experimental model of temporal lobe epilepsy. Neurosci Lett (2012) 0.82

Carbamazepine exerts anti-inflammatory effects in the rat. Eur J Pharmacol (1995) 0.80

Antiglutamic acid decarboxylase antibodies in children with encephalitis and status epilepticus. Pediatr Neurol (2012) 0.80

Seizures induced by NSAID. Allergy (1999) 0.79

Hashimoto's encephalopathy: documentation of mesial temporal seizure origin by ictal EEG. Seizure (2001) 0.78

Systemic lupus erythematosus (SLE)-like syndromes associated with carbamazepine therapy. Drug Saf (1991) 0.78